CG Oncology (CGON) Net Margin (2023 - 2026)

CG Oncology (CGON) has 4 years of Net Margin data on file, last reported at 40904.25% in Q1 2026.

• Quarterly Net Margin rose 19326498.0% year-over-year to 40904.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17088.9% (up 1204600.0% YoY) and the FY2025 annual result came in at 3985.02%, up 374447.0% from the prior year.
• Net Margin slipped to 40904.25% in Q1 2026, from 1764.69% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 1764.69% in Q4 2025 to a low of 2249000.0% in Q4 2023.
• A 4-year average of 255959.86% and a median of 17028.83% in 2024 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2024 — Net Margin surged 224202675 bps — and 2025, when it sank 23096847 bps.
• Tracing CGON's Net Margin over 4 years: stood at 2249000.0% in 2023, then surged by 100 bps to 6973.25% in 2024, then surged by 75 bps to 1764.69% in 2025, then slumped by 2218 bps to 40904.25% in 2026.
• The last three Net Margin figures came in at 40904.25% (Q1 2026), 1764.69% (Q4 2025), and 14071.67% (Q3 2025), per Business Quant data.